This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Fungal infection	IL-12; natural killer p30 receptor (Nkp30; NCR3; CD337)	<p>Patient and cell culture studies suggest IL-12 can increase Nkp30 expression and enhance anticytotoxic immunity. In patients with HIV/AIDS, Nkp30 expression was lower than that in healthy individuals. In NK cells from HIV-infected individuals, IL-12 stimulated Nkp30 expression and anticytotoxic activity. Next steps include identifying the fungal ligand for Nkp30 and elucidating downstream pathways. OncoSec Medical Inc. has a DNA plasmid coding IL-12 in Phase II testing to treat various cancers. Profectus BioSciences Inc. has DNA-encoded IL-12 in Phase I testing to treat HIV/AIDS. Intrexon Corp. also has DNA-encoded IL-12 in Phase II or earlier testing to treat various cancers.</p> <p>SciBX 6(45); doi:10.1038/scibx.2013.1294 Published online Nov. 21, 2013</p>	Patent filed; available for licensing or partnership via Innovate Calgary at the University of Calgary	<p>Li, S.S. <i>et al. Cell Host Microbe</i>; published online Oct. 16, 2013; doi:10.1016/j.chom.2013.09.007</p> <p>Contact: Christopher H. Mody, University of Calgary, Calgary, Alberta, Canada e-mail: cmody@ucalgary.ca</p>